

### Statement of Ownership, Management, and Circulation (All Periodicals Publications Except Requester Publications)

1. Publication Title: Pharmacological Reviews. 2. Publication Number: 0031-6997. 3. Filing Date: September 1, 2010. 4. Issue Frequency: quarterly in March, June, September, and December. 5. Number of Issues Published Annually: 4. 6. Annual Subscription Price: \$277.00. 7. Complete Mailing Address of Known Office of Publication: American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995; contact person: Richard Dodenhoff; telephone: 301-634-7997. 8. Complete Mailing Address of Headquarters of General Business Office of Publisher: American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995. 9. Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor: Publisher: American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995. Editor: Dr. David R. Sibley, Molecular Neuropharmacology Section, NINDS/NIH, 5625 Fishers Ln, Bethesda, MD 20892-9405. Managing Editor: Jill Filler, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995. 10. Owner: American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995. 11. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Securities: None. 12. Tax Status: The purpose, function, and nonprofit status of this organization and the exempt status for federal income tax purposes: Has Not Changed During Preceding 12 months. 13. Publication Title: Pharmacological Reviews. 14. Issue Date for Circulation Data: September 2010. 15. Extent and Nature of Circulation: Average No. Copies Each Issue During Preceding 12 Months: (a) Total Number of Copies (Net press run): 732. (b) Paid Circulation: (1) Mailed Outside-County Paid Subscriptions Stated on PS Form 3541: 369. (2) Mailed In-County Paid Subscriptions Stated on PS Form 3541: 0. (3) Paid Distribution Outside the Mails Including Sales Through Dealers and Carriers, Street Vendors, Counter Sales, and Other Paid Distribution Outside USPS®: 184. (4) Paid Distribution by Other Classes of Mail Through the USPS (e.g. First-Class Mail®): 0. (c) Total Paid Distribution (Sum of 15b. (1), (2), (3), and (4)): 553. (d) Free or Nominal Rate Distribution (By Mail and Outside the Mail): (1) Free or Nominal Rate Outside-County Copies Included on PS Form 3541: 25. (2) Free or Nominal Rate In-County Copies Included on PS Form 3541: 0. (3) Free or Nominal Rate Copies Mailed at Other Classes Through the USPS (e.g. First-Class Mail): 0. (4) Free or Nominal Rate Distribution Outside the Mail: 7. (e) Total Free or Nominal Rate Distribution: 32. (f) Total Distribution: 585. (g) Copies not Distributed: 147. (h) Total: 732. (i) Percent Paid: 94.5318. No. Copies of Single Issue Published Nearest to Filing Date: (a) Total Number of Copies (Net press run): 692. (b) Paid Circulation: (1) Mailed Outside-County Paid Subscriptions Stated on PS Form 3541: 386. (2) Mailed In-County Paid Subscriptions Stated on PS Form 3541: 0. (3) Paid Distribution Outside the Mails Including Sales Through Dealers and Carriers, Street Vendors, Counter Sales, and Other Paid Distribution Outside USPS®: 213. (4) Paid Distribution by Other Classes of Mail Through the USPS (e.g. First-Class Mail®): 0. (c) Total Paid Distribution: 599. (d) Free or Nominal Rate Distribution: (1) Free or Nominal Rate Outside-County Copies Included on PS Form 3541: 8. (2) Free or Nominal Rate In-County Copies Included on PS Form 3541: 0. (3) Free or Nominal Rate Copies Mailed at Other Classes Through the USPS (e.g. First-Class Mail): 0. (4) Free or Nominal Rate Distribution Outside the Mail: 3. (e) Total Free or Nominal Rate Distribution: 11. (f) Total Distribution: 610. (g) Copies not Distributed: 82. (h) Total: 692. (i) Percent Paid: 98.1967. 16. Publication of Statement of Ownership: Publication required. Will be printed in the December 2010 issue of this publication. 17. I certify that all information furnished on this form is true and complete. I understand that anyone who furnishes false or misleading information on this form or who omits material or information requested on the form may be subject to criminal sanctions (including fines and imprisonment) and/or civil sanctions (including civil penalties). Richard Dodenhoff, Journals Director, August 31, 2010.

## Take Advantage of Email Alerts

A free service providing email-based alerts for  
ASPET's journals!

*Customize alerts to meet your needs:*

- ◆ CiteTrack Alerts Including Citation Alerts and Keyword/Author Alerts
- ◆ Future Tables of Contents
  - ◆ *Fast Forward* (publish-ahead- of-print) articles
  - ◆ Tables of Contents
  - ◆ Announcements

*Create your alerts at:*


[JPET.aspetjournals.org/subscriptions](http://JPET.aspetjournals.org/subscriptions)  
[PHARMREV.aspetjournals.org/subscriptions](http://PHARMREV.aspetjournals.org/subscriptions)  
[MOLPHARM.aspetjournals.org/subscriptions](http://MOLPHARM.aspetjournals.org/subscriptions)  
[DMD.aspetjournals.org/subscriptions](http://DMD.aspetjournals.org/subscriptions)  
[MOLINTERV.aspetjournals.org/subscriptions](http://MOLINTERV.aspetjournals.org/subscriptions)



# SAVE THE DATE: April 9-13, 2011



2011 ASPET Annual Meeting  
at Experimental Biology 2011  
Washington, D.C.



## **2011 Preliminary Symposia:**

*Advances in Estrogen Receptor Signaling: Potential Implications For Women's Health*

*Autism and PDD: Neuropathology, Pharmacotherapies, and New Directions*

*Cardiovascular KCN1 (Kv7) Potassium Channels: Physiological Regulators and Targets for Therapeutic Intervention*

*Creating Effective Questions for Assessment and as Aids in Learning in Today's Pharmacology Programs*

*Drug Metabolism and Action in Pathophysiological Conditions*

*Gá Subtype-Selective Signaling By GPCRs as a Substrate for Functional Selectivity*

*G-Protein Coupled Receptor Signaling in Stem Cell Biology*

*Idiosyncratic Drug Reactions*

*Chronobiology in the Modern Curriculum – Addressing Disease Linkage and Pharmacological Approaches*

*Micro-RNA Controlled Regulation of Drug Metabolism and Disposition*

*New Roles for Arrestins in Signaling, Trafficking and Disease*

*Novel Regulation, Physiological Roles, and Pharmacological Intervention of GPCR-Adenylyl Cyclase Signaling Systems*

*Organ-Specific Toxicities Caused By Novel Metabolic Pathways*

*Pharmacogenomics and Personalized Medicine*

*Pharmacogenomics to Address Adverse Drug Events*

*Pharmacology for Healthcare Professionals: Thirst for Knowledge*

*Physiology and Pharmacology of Trace Amine Associated Receptors*

*Recent Developments In the Understanding of the Biology and Physiology of the Jak Family of Tyrosine Kinases*

*Regenerative Pharmacology and Translational Therapies for Repair Of Nerve and Muscle Diseases/Disorders*

*Role of Neuroinflammation in Psychiatric Disease*

*Systems Biology of Oxidative Stress and Therapeutic Implications*

*The Biological "Specifics" of the "Non-Specific" Placebo Response*

*The Neurobiology of Post Traumatic Stress Disorder (PTSD) and Implications for Treatment*

*Therapeutic Angiogenesis*


*Therapeutic Peptides: Novel Approaches in Drug Development*

*Therapeutic Targeting of Epoxyeicosanoids*

*Too Much or Too Little: Behavioral Models and Pharmacotherapies for Eating Disorders*

**For More Information Visit: [www.aspet.org/meetings](http://www.aspet.org/meetings)**

# RGS & AGS Proteins in Physiology & Disease Colloquium



**April 13-14, 2011, Washington, D.C.**

Chairs: John R. Hepler, Emory Univ & Venetia Zachariou, Univ of Crete  
This is a Satellite Meeting to Experimental Biology 2011

## RGS/AGS Proteins in Physiology & Disease

### **Visual System**

R7 RGS Regulation of Class A & Class C GPCR Pathways (*T. Wensel, Baylor College of Medicine*)  
AGS/PcP2/Go Signaling in Retina (*N. Vardi, Univ of Pennsylvania*)

### **Inflammation and Cardiovascular Disease**

RGS in Bronchial Smooth Muscle/Asthma (*K. Druey, NIAID/NIH*)  
RGS Modulation of Myocyte Stress Responses in Heart Disease (*D. Kass, Johns Hopkins Univ*)  
RGS Proteins in Cardiovascular Function (*S. Heximer, Univ of Toronto*)

### **Cancer and Neoplastic Disease**

RGS Proteins in Ovarian Cancer (*S. Hooks, Univ of Georgia*)  
AGS3 & Polycystic Kidney Disease (*P. Jackson, Genentech*)  
AGS Protein Pins in Asymmetric Cell Division (*K. Prehoda, Univ of Oregon*)

### **CNS Disorders**

RGS4 in Bipolar Disorders/Schizophrenia (*A. Hedge, Wake Forest Univ*)  
RGS10 in Microglia & CNS Inflammation (*M. Tansey, Emory Univ*)

## RGS & AGS Proteins & Their Partners as Drug Targets

### **The RGS/AGS/G Protein Interface as Drug Targets**

RGS Proteins as Drug Targets (*R. Neubig, Univ of Michigan*)  
Structure/Function of RGS & AGS Proteins (*D. Siderovski, Univ of North Carolina-Chapel Hill*)

### **Genetic Systems and Structure/Function**

AGS-3 Regulates  $G\alpha_o$  Signaling in *C. elegans* to Allow Behavioral Responses to Food  
Deprivation (*M. Koelle, Yale Univ*)  
Structural Analysis of RGS Protein Interactions (*J. Tesmer, Univ of Michigan*)

### **RGS/AGS Binding Partners and Signaling Complexes**

Ric8A Regulation of AGS/G Protein Complexes (*G. Tall, Univ of Rochester*)  
Coupling of RGS & AGS Proteins with GPCRs (*J. Blumer, Medical Univ of South Carolina*)

Attendees are invited to submit a poster for presentation on Wednesday evening and Thursday morning. Several short talks will be selected from the contributed posters. Poster titles and abstracts must be emailed to [araptakis@aspet.org](mailto:araptakis@aspet.org), no later than March 1, 2011.

**For more information and to register, visit:**

**[http://www.aspet.org/Meetings/RGS\\_AGS\\_Proteins/](http://www.aspet.org/Meetings/RGS_AGS_Proteins/)**